A personalized approach to the treatment of generalized myasthenia gravis

Generalized myasthenia gravis is a chronic autoimmune disorder characterized by an attack on the structures of the neuromuscular junction and by fluctuating muscle weakness and pathological fatigue, involving the ocular, bulbar, respiratory and skeletal muscles. Modern treatment of generalized myasthenia gravis aims to achieve sustained control of the disease, reduce the risk of exacerbations and myasthenic crises, and maintain the patient's quality of life. Some patients continue to experience a significant burden of disease, reduced daily activity, a need for longterm immunosuppressive therapy, and a risk of developing adverse events. A personalized approach to the treatment of generalized myasthenia gravis should take into account serological status, disease activity, the frequency of exacerbations, comorbidities, tolerance to treatment, the possibility of reducing the dose of glucocorticoids, and the patient's preferences.

1. Sanadze AG. Myasthenia and Myasthenic Syndromes. Series Specialist Doctor's Library. Moscow: GEOTAR-Media; 2019. 256 p. ISBN 978-5-9704-5170-0 (In Russ.).

2. Narayanaswami P, Sanders DB, Wolfe GI, et al. International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update. Neurology. 2021;96(3):114-22. doi: 10.1016/S1474-4422(24)00028-0

3. Gilhus NE, Tzartos S, Evoli A, et al. Myasthenia gravis. Nat Rev Dis Primers. 2019 May 2;5(1):30. doi: 10.1038/s41572-019-0079-y

4. McCallion J, Borsi A, Noel W, et al. Systematic review of the patient burden of generalized myasthenia gravis. BMC Neurol. 2024 Feb 10;24(1):61. doi: 10.1186/s12883-024-03553-y

5. Dewilde S, Phillips G, Paci S, et al. The Burden Patients with Myasthenia Gravis Experience in Terms of Breathing, Fatigue, Sleep, Mental Health, Discomfort and Usual Activities in Comparison to the General Population. Adv Ther. 2024 Jan;41(1):271-91. doi: 10.1007/s12325-023-02704-w

6. Narayanaswami P, Sanders DB, Wolfe GI, et al. Comparative effectiveness of azathioprine and mycophenolate mofetil for myasthenia gravis (PROMISE-MG): a prospective cohort study. Lancet Neurol. 2024 Mar;23(3):267-76. doi: 10.1016/S1474-4422(24)00028-0

7. Wiendl H, Abicht A, Chan A, et al. Guideline for the management of myasthenic syndromes. Ther Adv Neurol Disord. 2023 Dec 26:16:17562864231213240. doi: 10.1177/17562864231213240

8. Meisel A, Sacca F, Spillane J, et al. Expert consensus recommendations for improving and standardising the assessment of patients with generalised myasthenia gravis. Eur J Neurol. 2024 Jul;31(7):e16280. doi: 10.1111/ene.16280

9. Dresser L, Wlodarski R, Rezania K, Soliven B. Myasthenia Gravis: Epidemiology, Pathophysiology and Clinical Manifestations. J Clin Med. 2021 May 21;10(11):2235. doi: 10.3390/jcm10112235

10. Gummi RR, Kukulka NA, Deroche CB, Govindarajan R. Factors associated with acute exacerbations of myasthenia gravis. Muscle Nerve. 2019 Dec;60(6):693-9. doi: 10.1002/mus.26689

11. Clardy SL, Smith TL. Therapeutic Approach to Autoimmune Neurologic Disorders. Continuum (Minneap Minn). 2024 Aug 1;30(4):1226-58. doi: 10.1212/CON.0000000000001463

12. , Mantegazza R, Antozzi C. From Traditional to Targeted Immunotherapy in Myasthenia Gravis: Prospects for Research. Front Neurol. 2020 Sep 2;11:981. doi: 10.3389/fneur.2020.00981

13. Menon D, Barnett C, Bril V. Novel Treatments in Myasthenia Gravis. Front Neurol. 2020 Jun 30;11:538. doi: 10.3389/fneur.2020.00538

14. Albazli K, Kaminski HJ, Howard JF. Complement inhibitor therapy for myasthenia gravis. Front Immunol. 2020 Jun 3:11:917. doi: 10.3389/fimmu.2020.00917

15. Vlasov YaV, Merkulov YuA, Alifirova VM, et al. Results of medical and social research and assessment of quality of life in myasthenia gravis. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2025;17(5):11-20 (In Russ.). doi: 10.14412/2074-2711-2025-5-11-20

16. Thomsen JLS, Andersen H. Outcome Measures in Clinical Trials of Patients With Myasthenia Gravis. Front Neurol. 2020 Dec 23:11:596382. doi: 10.3389/fneur.2020.596382

17. Mantegazza R, Antonini G, Gastaldi M, et al. Use of Corticosteroids in Myasthenia Gravis: Expert Opinion for Daily Management. Neurol Ther. 2025 Oct;14(5):2063-81. doi: 10.1007/s40120-025-00796-w

18. Galati A, Brown ES, Bove R, et al. Glucocorticoids for therapeutic immunosuppression: clinical pearls for the practicing neurologist. J Neurol Sci. 2021 Nov 15;430:120004. doi: 10.1016/j.jns.2021.120004

19. Murai H. The Japanese clinical guidelines 2022 for myasthenia gravis and Lambert-Eaton myasthenic syndrome. Brain Nerve. 2024 Jan;76(1):7-12. doi: 10.11477/mf.1416202551

20. Sahashi K, Engel AG, Lambert EH, et al. Ultrastructural localization of the terminal and lytic ninth complement component at the motor end-plate in myasthenia gravis. J Neuropathol Exp Neurol. 1980; Mar;39(2):160- 72. doi: 10.1097/00005072-198003000-00005

21. Shelly S, Gotkine M, Wilf Yarkoni A, et al. National guidelines for diagnosis, treatment, and management of myasthenia gravis in Israel. Ther Adv Neurol Disord. 2025;18:17562864251361607. doi: 10.1177/17562864251361607

22. Vu T, Meisel A, Mantegazza R, et al. Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis. NEJM Evid. 2022;1(5):EVIDoa2100066 doi: 10.1056/EVIDoa2100066

23. Vu TH, Mantegazza R, Annane D, et al. Long-Term Efficacy and Safety of Ravulizumab in Adults With Anti-Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis: Final Results From the Phase 3 CHAMPION MG Open-Label Extension. Eur J Neurol. 2025;32(4):e70158 doi: 10.1111/ene.70158

24. Narayanaswami P, Pulley MT, Macwan SP, et al. Effectiveness and Safety of Ravulizumab in Generalized Myasthenia Gravis: Updated Analysis from a Global Registry (P1-11.014). Neurology. 2025;104(7 Suppl 1):1829. doi: 10.1212/WNL.0000000000208771

25. Jindal S, Vestergaard Pedersen D, Gera N, et al. Characterization of the bispecific VHH antibody gefurulimab (ALXN1720) targeting complement component 5, and designed for low volume subcutaneous administration. Mol Immunol. 2024;165:29-41 doi: 10.1016/j.molimm.2023.12.004

26. Gerischer L, Doksani P, Hoffmann S, Meisel A. New and Emerging Biological Therapies for Myasthenia Gravis: A Focussed Review for Clinical Decision-Making. BioDrugs. 2025;39(2):185-213 doi: 10.1007/s40259-024-00701-1

27. Gwathmey KG, Sacca F, Howard JF Jr, et al. Efficacy and safety of subcutaneous self-administered gefurulimab in generalized myasthenia gravis: primary results from the phase 3, randomized, double-blind, placebo-controlled PREVAIL trial. Presented at: American Academy of Neurology Annual Meeting; 2026. Abstract 61544. Available at: https://www.aan.com/msa/Public/Events/AbstractDetails/61544

28. Howard JF Jr, Utsugisawa K, Benatar M, et al. Safety and efficacy of eculizumab in antiacetylcholine receptor antibody-positive refractory generalised myasthenia gravis: REGAIN. Lancet Neurol. 2017 Dec;16(12):976-86. doi: 10.1016/S1474-4422(17)30369-1

29. Meisel A, Annane D, Vu T, et al. Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis. J Neurol. 2023 Aug;270(8):3862-75. doi: 10.1007/s00415-023-11699-x